COVID-19: an unexpected indication for anti-rheumatic therapies?
Identifieur interne : 001778 ( Main/Corpus ); précédent : 001777; suivant : 001779COVID-19: an unexpected indication for anti-rheumatic therapies?
Auteurs : Bruno Lucchino ; Manuela Di Franco ; Fabrizio ContiSource :
- Rheumatology (Oxford, England) [ 1462-0332 ] ; 2020.
English descriptors
- KwdEn :
- Adalimumab (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Antirheumatic Agents (therapeutic use), Azetidines (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Chloroquine (therapeutic use), Clinical Trials as Topic (MeSH), Coronavirus Infections (drug therapy), Cytokine Release Syndrome (virology), Drug Repositioning (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (drug therapy), SARS-CoV-2 (MeSH), Sulfonamides (therapeutic use).
- MESH :
- chemical , therapeutic use : Adalimumab, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Azetidines, Chloroquine, Hydroxychloroquine, Sulfonamides.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- virology : Cytokine Release Syndrome.
- Betacoronavirus, COVID-19, Clinical Trials as Topic, Drug Repositioning, Humans, Pandemics, SARS-CoV-2.
DOI: 10.1093/rheumatology/keaa194
PubMed: 32374874
PubMed Central: PMC7239095
Links to Exploration step
pubmed:32374874Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COVID-19: an unexpected indication for anti-rheumatic therapies?</title><author><name sortKey="Lucchino, Bruno" sort="Lucchino, Bruno" uniqKey="Lucchino B" first="Bruno" last="Lucchino">Bruno Lucchino</name><affiliation><nlm:affiliation>Rheumatology Unit, Department of Internal Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Di Franco, Manuela" sort="Di Franco, Manuela" uniqKey="Di Franco M" first="Manuela" last="Di Franco">Manuela Di Franco</name><affiliation><nlm:affiliation>Rheumatology Unit, Department of Internal Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Conti, Fabrizio" sort="Conti, Fabrizio" uniqKey="Conti F" first="Fabrizio" last="Conti">Fabrizio Conti</name><affiliation><nlm:affiliation>Rheumatology Unit, Department of Internal Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32374874</idno><idno type="pmid">32374874</idno><idno type="doi">10.1093/rheumatology/keaa194</idno><idno type="pmc">PMC7239095</idno><idno type="wicri:Area/Main/Corpus">001778</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001778</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">COVID-19: an unexpected indication for anti-rheumatic therapies?</title><author><name sortKey="Lucchino, Bruno" sort="Lucchino, Bruno" uniqKey="Lucchino B" first="Bruno" last="Lucchino">Bruno Lucchino</name><affiliation><nlm:affiliation>Rheumatology Unit, Department of Internal Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Di Franco, Manuela" sort="Di Franco, Manuela" uniqKey="Di Franco M" first="Manuela" last="Di Franco">Manuela Di Franco</name><affiliation><nlm:affiliation>Rheumatology Unit, Department of Internal Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Conti, Fabrizio" sort="Conti, Fabrizio" uniqKey="Conti F" first="Fabrizio" last="Conti">Fabrizio Conti</name><affiliation><nlm:affiliation>Rheumatology Unit, Department of Internal Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Rheumatology (Oxford, England)</title><idno type="eISSN">1462-0332</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adalimumab (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Azetidines (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Chloroquine (therapeutic use)</term><term>Clinical Trials as Topic (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Cytokine Release Syndrome (virology)</term><term>Drug Repositioning (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>SARS-CoV-2 (MeSH)</term><term>Sulfonamides (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adalimumab</term><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term><term>Azetidines</term><term>Chloroquine</term><term>Hydroxychloroquine</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Cytokine Release Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>COVID-19</term><term>Clinical Trials as Topic</term><term>Drug Repositioning</term><term>Humans</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32374874</PMID><DateCompleted><Year>2020</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1462-0332</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>06</Month><Day>01</Day></PubDate></JournalIssue><Title>Rheumatology (Oxford, England)</Title><ISOAbbreviation>Rheumatology (Oxford)</ISOAbbreviation></Journal><ArticleTitle>COVID-19: an unexpected indication for anti-rheumatic therapies?</ArticleTitle><Pagination><MedlinePgn>1200-1203</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/rheumatology/keaa194</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lucchino</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Internal Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Franco</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Internal Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conti</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Internal Clinical, Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Rheumatology (Oxford)</MedlineTA><NlmUniqueID>100883501</NlmUniqueID><ISSNLinking>1462-0324</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001384">Azetidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>FYS6T7F842</RegistryNumber><NameOfSubstance UI="D000068879">Adalimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>ISP4442I3Y</RegistryNumber><NameOfSubstance UI="C000596027">baricitinib</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Rheumatology (Oxford). 2020 Jul 1;59(7):1769-1770</RefSource><PMID Version="1">32472681</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000068879" MajorTopicYN="N">Adalimumab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001384" MajorTopicYN="N">Azetidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>03</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32374874</ArticleId><ArticleId IdType="pii">5831165</ArticleId><ArticleId IdType="doi">10.1093/rheumatology/keaa194</ArticleId><ArticleId IdType="pmc">PMC7239095</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):420-422</Citation><ArticleIdList><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol Sin. 2020 Mar 3;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32125642</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunother Cancer. 2018 Jun 15;6(1):56</Citation><ArticleIdList><ArticleId IdType="pubmed">29907163</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2007 Oct;30(4):297-308</Citation><ArticleIdList><ArticleId IdType="pubmed">17629679</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Mar 09;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Feb 24;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation><ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2020 Apr 16;181(2):271-280.e8</Citation><ArticleIdList><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation><ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):e30-e31</Citation><ArticleIdList><ArticleId IdType="pubmed">32032529</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Anal. 2020 Apr;10(2):102-108</Citation><ArticleIdList><ArticleId IdType="pubmed">32282863</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Respir J. 2015 Feb;45(2):428-39</Citation><ArticleIdList><ArticleId IdType="pubmed">25359346</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Mar 20;:105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2018 Jul;155:67-75</Citation><ArticleIdList><ArticleId IdType="pubmed">29753658</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2005 Jul 7;436(7047):112-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16001071</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7809-14</Citation><ArticleIdList><ArticleId IdType="pubmed">18490652</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2020 Apr;20(4):400-402</Citation><ArticleIdList><ArticleId IdType="pubmed">32113509</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001778 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001778 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32374874
|texte= COVID-19: an unexpected indication for anti-rheumatic therapies?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32374874" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |